Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 16/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580317 | 1.00 | CTSA (0.51) | CTSAKEAP1NFE2L2CYP2C19CYP1A2 | |
| SCHEMBL580171 | 0.90 | TNF (0.49) | CTSACYP2C19CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL580496 | 0.83 | CYP1A2 (0.43) | CTSACYP2C19CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL579703 | 0.83 | CYP1A2 (0.43) | CTSACYP2C19CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL30232579 | 0.82 | KMT2A (0.54) | CTSAKEAP1NFE2L2NPSR1 | |
| SCHEMBL617039 | 0.82 | KMT2A (0.54) | CTSAKEAP1NFE2L2NPSR1 | |
| SCHEMBL9222644 | 0.81 | POLB (0.55) | CTSAKEAP1NFE2L2NPSR1 | |
| SCHEMBL9228033 | 0.81 | NPSR1 (0.54) | CTSACYP2C19CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5198568 | 0.80 | NPSR1 (0.47) | CTSAKEAP1NFE2L2MAPK1NPSR1 | |
| SCHEMBL14387382 | 0.79 | CTSA (0.44) | CTSAMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633695-B1 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | BRIDGE PHARMA INC (US) | 2012-02-15 | — | — | EP | disclosed |
| US-7141696-B2 | Smooth muscle spasmolytic agents | BRIDGE PHARMA, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040248987-A1 | Smooth muscle spasmolytic agents | BRIDGE PHARMA, INC. | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248987-A1 | Smooth muscle spasmolytic agents | MYLK, TNNC1, MYLK2 | CTSA 1492/4885KEAP1 1142/4885NFE2L2 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.